33 results about "Antigenicity" patented technology

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

This invention discloses a monkeypox virus nanoparticle vaccine based on an HBc-VLP vector, its preparation method, and its application, belonging to the field of biomedical technology. The vaccine uses HBc-VLP as a backbone with SpyCatcher sites on its surface. Through a SpyTag / SpyCatcher coupling system, antigenic polypeptides derived from the monkeypox virus M1R protein (containing overlapping epitopes for B cells and T cells) are loaded onto the VLP surface in a high-density, directed, and stable manner. This design mimics the structure of natural viral particles and can efficiently activate humoral and cellular immunity. The epitopes, screened by immunoinformatics, exhibit high antigenicity, broad-spectrum HLA affinity, and are non-toxic and non-sensitizing. This invention also provides an immunomodulatory composition containing this vaccine and its application in the preparation of drugs for the prevention or treatment of monkeypox virus infection. The vaccine preparation process is simple, has strong antigen compatibility, and has good industrialization prospects.

The present invention belongs to the technical field of biological detection, and in particular to an indirect ELISA detection kit for infectious bovine rhinotracheitis virus (IBRV) antibodies and use thereof. Based on the good antigenicity of an IBRV gE protein, the present invention endows the indirect ELISA detection kit and an indirect ELISA detection method for IBRV, established based on the IBRV gE protein, with characteristics of sensitivity, specificity, and high efficiency. The method is simple to operate, time-efficient, and cost-effective, allowing for high-throughput detection of cattle infected with IBRV, and provides a simple and effective diagnostic tool for clinical diagnosis of infectious bovine rhinotracheitis (IBR).

The application discloses a system and method for predicting an influenza virus evolution track, and the system comprises a virus evolution track search model and a virus track prediction module; the virus track diffusion model comprises a diffusion training module, a fusion module, a time attention module, a space attention module and a track optimization module; the application proposes a sampling strategy for the influenza virus evolution track based on the low genetic diversity and antigenicity of the influenza virus, constructs an influenza virus evolution track dataset through the proposed sampling strategy, generates the influenza virus evolution track by using a diffusion model with the fusion module and the space-time attention module, and predicts the evolution track of the influenza virus.

This invention discloses a ginsenoside membrane hybrid tumor nanovaccine, a pharmaceutical composition, its preparation method, and its applications. The ginsenoside membrane hybrid tumor nanovaccine comprises a fusion membrane formed by a macrophage membrane and a lipid membrane; wherein, a tumor antigen peptide-MHC complex is bound to the surface of the macrophage membrane, and the lipid membrane comprises ginsenosides and phospholipids. This ginsenoside membrane hybrid tumor nanovaccine and the pharmaceutical composition containing it simultaneously possess excellent effects such as high antigenicity, broad-spectrum activity, high targeting, high adjuvant potency, and safety, demonstrating superior efficacy in practical applications; furthermore, the entire preparation process is simple to operate and has good reproducibility.

The application discloses a detection kit capable of distinguishing porcine Senecavirus infection or vaccine immunization, and belongs to the technical field of animal virus antibody detection. VP2-VP3-VP1 and 3AB-3C recombinant proteins used in the application have stronger antigenicity and diagnostic sensitivity when used for detecting porcine Senecavirus, can effectively distinguish natural infection from vaccine immunization, and thus realize accurate detection. In addition, the detection method also has good specificity, analysis sensitivity, repeatability and reproducibility, has a wider application range, and has important application value.

This invention provides a recombinant type III collagen, nucleic acid, expression vector, strain, and its applications. A recombinant type III collagen is obtained through genetic engineering. Using synthetic biology techniques, collagen can be synthesized and produced using modified microbial chassis cells. The recombinant collagen produced in this way exhibits high expression levels, excellent cell proliferation effects, low toxicity, low antigenicity, low immunogenicity, the ability to guide cell regeneration, and good biocompatibility. When applied to humans, it produces a low immune response. The production method is simple, environmentally friendly, and has broad application prospects in the biopharmaceutical, cosmetic, and skincare industries.

This application provides a method for preparing decellularized pericardium, employing a combination of specific pretreatment, sterilization, defatting, decellularization, and freeze-drying processes. This method effectively removes antigenic substances from animal tissues while maximally preserving the integrity of bioactive components and structures in the material. Simultaneously, the preparation process effectively incorporates inorganic metal ions, polysaccharides, and drugs to prevent adhesions. The resulting decellularized pericardium possesses both natural rough and smooth surfaces. The smooth surface has a dense fibrous structure, effectively blocking the invasion of adhesion tissues without affecting tendon function. The rough surface allows tissue ingrowth, facilitating rapid vascularization and tendon repair. Furthermore, the decellularized pericardium is loaded with functional components, further promoting tendon healing and preventing adhesions.

The invention describes peptides with anticancer activity and exhibiting antagonistic activity against CD133 protein, which were obtained and designed by means of computer tools, evaluating physicochemical parameters of flexibility, hydrophilicity, hydrophobicity, antigenicity and total charge as described herein, in addition to the modeling of the protein, which allowed selecting 4 regions with the appropriate characteristics. After modeling the selected peptides, CD133 peptide-protein molecular docking was performed, where stable interactions were observed, even showing hydrogen bonds. Finally, the peptides of the invention showed anticancer effects against several cancer cell lines, including cancer cells resistant to conventional treatments such as triple negative breast cancer cells.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.

The application discloses a polypeptide for detecting type 1 RHDV antibody, and an amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. The polypeptide is applied to preparing a kit for detecting type 1 RHDV antibody and is applied to detecting type 1 RHDV antibody. The application further discloses a kit for detecting type 1 RHDV antibody, which comprises the polypeptide for detecting type 1 RHDV antibody. The kit for detecting type 1 RHDV antibody is applied to detecting type 1 RHDV antibody. The polypeptide for detecting type 1 RHDV antibody has high specificity for type 1 RHDV antibody, is safe and has good antigenicity. The kit for detecting type 1 RHDV antibody is suitable for an indirect ELISA detection method, can evaluate type 1 RHDV antibody level, has high specificity and sensitivity and is suitable for detecting batch samples.

Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also describe

A recombinant multi-epitope immunogenic polypeptide derived from *C. bancroftian* and its applications are disclosed. The amino acid sequence of the recombinant multi-epitope immunogenic polypeptide includes a fragment of the *Mycobacterium tuberculosis* 50S ribosomal protein L7 / L12, a cytotoxic T lymphocyte epitope, a helper T lymphocyte epitope, and a linear B cell epitope, formed by tandem linkers. The nucleotide coding sequence of the polypeptide is also disclosed. This invention further discloses a recombinant expression vector containing the nucleic acid molecule, a host cell containing the recombinant expression vector, an immunogenic composition containing the recombinant multi-epitope immunogenic polypeptide, and a method for preparing the recombinant multi-epitope immunogenic polypeptide. Immuninformatics analysis results show that the polypeptide is antigenic, non-sensitizing, and non-toxic; structural prediction, molecular docking, and computer immunosimulation results suggest its application potential as a candidate immunogenic polypeptide related to *C. bancroftian*.

The application discloses a kind of recombinant type I humanized collagen and its preparation method and application, belong to genetic engineering field, by bioinformatics method to the core function fragment of human type I collagen alpha 1 chain as shown in SEQ ID NO.1 is analyzed, design and construct the length of 330 amino acids of recombinant type I humanized collagen rCol1, sequence as shown in SEQ ID NO.3;Recombinant type I humanized collagen rCol1 is hydrophilic protein, with good biocompatibility, and with lower antigenicity, can efficiently promote Schwann cell and neuron neurite regeneration;The recombinant type I humanized collagen rCol1 prepared by the method has high purity, no virus hidden danger, has obvious expression abundance;This protein has important application in biomedical, regenerative medicine, tissue engineering, beauty care and cosmetic preparation and the like.

The present invention relates to a synthetic nucleic acid molecule including a 3'-UTR polynucleotide having improved translation efficiency and a vaccine composition including the same, and more particularly, to a synthetic nucleic acid molecule including a 3'-UTR having improved translation efficiency prepared by including a specific motif, a codon-optimized signal sequence, and an antigen-encoding sequence, and a vaccine composition including the same. The synthetic nucleic acid molecule according to the present invention includes a 3'-UTR polynucleotide having improved translation efficiency, which can effectively induce expression of an antigenic polypeptide, which is useful for vaccine development in that it can be expected to increase immunogenicity as a vaccine.

The application discloses an O-type foot-and-mouth disease virus multi-epitope virus-like particle nano-antigen and a preparation method and application thereof. The nano-antigen is obtained by sequentially connecting antigen epitopes of three topological representative strains O / Tibet / CHA / 99, O / Mya98 / BY / 2010, OZK / 93, O / XJPS / CHA / 2017 and O / HKN / 2007 of the O-type foot-and-mouth disease virus in sequence, introducing a T cell epitope of a 3A gene of the foot-and-mouth disease virus at a C terminal, and finally inserting a woodchuck hepatitis B virus core antigen, and an amino acid sequence of the nano-antigen is shown as SEQ ID NO. 6. Immunological test results show that the nano-antigen has good antigenicity, a vaccine prepared from the nano-antigen can not only induce high-level protective antibodies, but also protect immunized animals against virus attack. In addition, the nano-antigen has immunoprotective effects on the O-type foot-and-mouth diseases of pigs, cattle and sheep. The application provides an effective technical means for preventing and controlling and purifying the foot-and-mouth disease.

The present invention relates to a synthetic protein comprising at least one synthetic amino acid bearing a diene group and at least one thioether bond, to a method for preparing said synthetic protein and to the use of said synthetic protein for the preparation of a pharmaceutical composition.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and / or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.

Provided herein are engineered hCMV gB polypeptides. In some aspects, the engineered gB polypeptides exhibit enhanced conformational stability and / or antigenicity. Methods are also provided for use of the engineered gB polypeptides as diagnostics, in screening platforms, and / or in vaccine compositions.

The application discloses a fusion protein HP13138PB and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, HBD-3, PSM alpha 4 and PADRE. The application screens 34 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and sensitization, and have the characteristics of high population coverage and the like. The immunogenicity of the vaccine is improved by further adding antibacterial peptide HBD-3 and auxiliary peptide PADRE, and PSM alpha 4 is added to endow the vaccine with targeted delivery function. In-vitro experiments prove that HP13138PB can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The HP13138PB as a vaccine has the advantages of simple preparation method, low cost, high yield and higher safety and the like. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The present invention addresses the problem of providing: a new antigen that can also be effective against mutant viruses; and a new vaccine obtained by using said antigen. Said problem is solved by providing a lipopeptide which is obtained by conjugating a lipid and a peptide and in which the peptide has antigenicity and is represented by formula (1): a-b-c-d(-e-f)n. In the formula, n represents 0 or 1, and a-f include a specific amino acid.

This invention discloses the polypeptide fusion protein CP13138P and its application in tuberculosis prevention. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, CTB, Pam2Cys, and PADRE. This invention screened 34 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. In vitro experiments demonstrate that CP13138P can stimulate an immune response in human peripheral blood mononuclear cells (PBMCs), increasing IFN-γ in PBMCs. + The number of T lymphocytes is significantly increased, and they secrete significantly high levels of more than a dozen cytokines, including G-CSF, making them a dominant protective antigen. CP13138P, as a vaccine, has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The application provides a respiratory syncytial virus antigenic polypeptide, nucleic acid and vaccine and application thereof. The application first provides a respiratory syncytial virus antigenic polypeptide or an immunogenic fragment thereof, wherein the amino acid sequence of the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment thereof has one or more mutation sites of amino acid residues at positions 174-176, 181-184, 210-213 and 160-161 compared to the amino acid sequence of a wild-type Pre-F protein of the respiratory syncytial virus. The application also provides a respiratory syncytial virus vaccine mRNA vaccine encoding the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment thereof. The application can improve the pre-F immunogenicity and / or help to improve the protein expression level.

The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.